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ABSTRACT
Obstructive sleep apnoea (OSA) is a leading public health problem both in the developed and developing nations. However,
awareness regarding diagnostic options, management and consequences of untreated OSA remains inadequate. In
developing nations, the resources for adequate sleep medicine facilities are scarce. Therefore, there is a need for low cost,
simple and accurate diagnostic and therapeutic modalities exists. Untreated OSA leads to excessive daytime sleepiness,
diminished performance and an overall poor quality of life. The role of OSA in promoting insulin resistance, atherosclerosis,
hypertension and a procoagulant state has now been established. Newer insights into the biochemical and genetic mediators
of OSA have raised hopes regarding the development of a “cure”. However, as of now, continuous positive airway pressure
(CPAP) therapy remains the first-line treatment. Though its use improves the quality of life as well as metabolic
derangements observed in OSA, patients’ acceptance remains low. Its high cost and long-term use are also cumbersome.
Newer modes of delivering CPAP, oral appliances and upper airway surgery are the other options available. It is hoped that
their appropriate use to increase patients’ compliance may improve the quality of life as well as provide a survival benefit.
[Indian J Chest Dis Allied Sci 2008; 50: 137-150]
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INTRODUCTION
“Sleep is a reward for some, a punishment for others”
Issador Ducasse
Sleep disordered breathing (SDB) includes a spectrum
of conditions, the most severe of which is obstructive
sleep apnoea syndrome (OSAS). It is a potentially
disabling condition characterised by disruptive snoring,
repeated episodes of complete or partial pharyngeal
obstruction during sleep resulting in nocturnal
hypoxemia, frequent arousals and excessive daytime
sleepiness.
Ever since Charles Dickens described a “Pickwickian
stereotype”, obstructive sleep apnea (OSA) has literally
walked out of books to flourish around us in various
under appreciated forms. Among adults, sleep apnea is
more common than asthma. Recognised as a separate
clinical entity nearly 35 years ago, OSA still remains a
substantial but frequently ignored public health threat.
Apnoea is defined as complete cessation of nasal
airflow for more than 10 seconds.1 Hypopnoea is
characterised by polysomnographic (PSG) variables as
any one of the three,1 namely, decrease in nasal airflow
by more than 50% for more than 10 sec, decrease in
nasal airflow by less than 50% with a more than 3% fall
in oxygen saturation or a decrease in nasal airflow by
less than 50% with electroencephalographic (EEG)
evidence of arousal. As hypopnoeas lead to the same
clinical consequences as apneas, the apnoea-hypopnoea
index (AHI) is widely used for the diagnosis and the
assessment of the severity of OSA.1 The AHI or
respiratory disturbance index (RDI) refers to the mean
number of apnoeas or hypopneas per hour of sleep. An
AHI of more than five on overnight PSG study is
required for the diagnosis of OSA.1 A respiratory event
related arousal (RERA) is defined as increasing
respiratory effort required to maintain a normal airflow
culminating in an arousal on EEG. The OSAS requires a
minimum presence of excessive daytime sleepiness.1
The present classification of sleep disorders2 is described
in table 1.
EPIDEMIOLOGY
Several global epidemiological studies3-12 have
demonstrated a variable prevalence of OSAS (0.3 to
5.1%) (Table 2). In a recent summary pooling together
three studies, it was estimated that 20% of adults with
body mass index (BMI) in the range 25-28 have sleep
apnoea based on a cut-off apnoea-hypopnoea index
(AHI)>5 and 7% based on an AHI>15.13 These estimates,
however, are based on data from predominantly white
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urban adults to be 9.4% and that of OSAS to be 2.7
percent. The prevalence of OSA and OSAS in males was
13.4% and 4%, respectively while that in females was
5.6% and 1.5 percent. It was a two-stage study which
screened 2505 subjects with a response rate of 62%
(Table 3).
RISK FACTORS
Several factors have been hypothesised to have a role in
the development and progression of OSA.18,19 Some are
not modifiable like ethnicity, age, gender while others
like excess weight, alcohol, smoking, nasal congestion
and postmenopausal status are highly prevalent.
Nonmodifiable Risk Factors
Age. The prevalence of OSA increases with age. In
midlife and in elderly (>65 years) it is found to be 2 to 3
times higher than among the middle aged (35-64 years)
men and women.18 But this increase is not continual and
there is a plateau in prevalence rate after 65 years of
age.18 It has been seen that there is little or no association
of OSA with sleepiness, hypertension, or decrement in
cognitive function in elderly, all of which are common
correlates of OSA in middle ages. Association with BMI
is weaker and prevalence of self-reported snoring is
lesser as compared to middle age. There is a higher
incidence of central sleep apnoea in elderly. Prevalence
of OSAS in childhood varies between one percent to 1.8
percent.18 In contrast to adults, there is an equal
prevalence in either sex. Obesity is a less important risk
factor for OSA in childhood. Daytime sleepiness is less
commonly identified in children with OSA, but poor
school performance is seen in 16% to 71% of them.
Table 1. Current terminology for common sleep related
breathing disorders
Primary central apnoea
Central sleep apnoea due to
Cheyne stokes breathing
High altitude periodic breathing
Drugs (barbiturates, morphine, sedative antihistaminics etc)
Medical conditions apart from Cheyne Stokes
(hypothyroidism, renal failure, stroke, pregnancy etc)
Primary sleep apnoea of infancy
Obstructive sleep apnoea (OSA)
Sleep related non-obstructive alveolar hypoventilation; idiopathic
Congenital central alveolar hypoventilation syndrome
The American Sleep Disorders Association Arbitrarily Classifies
OSA as
Mild OSA AHI 5-15
Moderate OSA AHI 15-30
Severe OSA AHI ≥ 30
Table 2. Prevalence rates of sleep disorderd breathing in various international studies
Year Author and Place Study Design Sample PSG Age Estimated Prevalence (%)
Size (n) (N) (yr) HS OSA OSAS
1988 Gislason et al (Sweden)3 Population based 4,064 61 30-60  15 3 1.4
1993* Young et al (Wisconsin, USA)4 Population based 3,513 624 30-60  36 9(F), 24(M) 2(F), 4(M)
1994 Bearpark et al (Australia)5 Population based NA 294 40-65  22 26 3.1
1994 Olson et al (Australia)6 Population based 1,188 193 35-69 24 13.5 4.2
2001* Bixler et al (Pennsylvania, USA)8 Population based 16,603 1,741 20-99  33 17 3.5
2001* Duran et al (Spain)9 Population based 2,794 400 30-70  35 26(F), 28(M) 3.2
* = Studies with similar design and defining criteria; PSG = Polysomnography;  N = No. of polysomnography studies done,
HS = Habitual snorers, OSA = Obstructive sleep apnoea, OSAS = Obstructive sleep apnoea syndrome, NA = Not available, M = Males;
F = Females.
Table 3. Prevalence rates of sleep disordered breathing in India
Year Author and Place Study Population PSG Age Estimated Prevalence† %
(Questionnaire based) (N) (yr) HS OSA OSAS
2004 Udwadia et al15 (Mumbai) Male insurance claimers (658) 254 35-65 26.0 19.5 7.5
2006 Sharma et al16 (New Delhi) Community study (2150) 150 30-60 23.0 13.7 3.8
2007 Reddy17 (New Delhi) Community study (2505) 356 30-60 18.1 9.4 2.7
† = Estimations based on number of PSG studies done with extrapolation to the screened population; PSG = Polsomnography,
N=No. of polysomnography studies, HS = Habitual snorers, OSA = Obstructive sleep apnoea, OSAS = Obstructive sleep apnoea
syndrome
populations and may not be applicable to other racial
groups. Major aetiological factors such as obesity and
craniofacial anatomical predispositions are both
genetically and environmentally influenced. Estimates
of OSAS prevalence in Asian population are similar12, 14,
15 (2-4%). It is likely that apart from obesity, other strong
risk factors such as craniofacial features and ethnicity
may be contributory to high prevalence of OSA in Asian
population. Only two community-based prevalence
studies have been done from India so far.16, 17 The first
conducted in a small sample of semi urban population
in Delhi revealed that at least 13.7% and 3.8% of middle-
aged Indian adults have OSA and OSAS, respectively.16
Unpublished results from a recently completed
community-based prevalence study covering a wide
socio-economic base, the South Delhi Sleep Study
(SDSS)17  found the prevalence of OSA in middle-aged
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Adenotonsillar hypertrophy is an important treatable
cause of sleep disorderd breathing (SDB) in children.18
Male gender. In majority of the population-based
studies, male sex is a striking risk factor for OSA and a
2-3-fold greater risk of OSA has been reported for men
compared with women.19 The gender related protective
effect decreases in postmenopausal women who are not
receiving hormone replacement therapy. In addition to
the lesser likelihood of women being evaluated and
treated for OSA, effect of sex hormones, craniofacial
morphology, pattern of fat deposition, differences in
upper airway shape and genioglossal muscle activity
during the awake state and control of ventilation,  have
been proposed to account for a higher male risk of
OSA.20  However, a reduction in the AHI on
administration of estrogen and progesterone to men (or
postmenopausal women) has not been demonstrated.20
The effect of exposure to exogenous potential risk
factors, such as occupational exposures or smoking, to
explain the gender difference has also not been studied
adequately till date.  The  observation  that  female
patients with  OSA have a  poorer  survival  indicates
that  OSA  is either probably diagnosed late in the
course of the disease or is not treated aggressively
enough in females.19
Ethnicity. Population-based studies3-11 suggest that
the prevalence of OSAS is higher in African-Americans
as compared with Caucasians.  It is hypothesised that
other strong OSA risk factors, apart from obesity, such
as craniofacial features that compromise the upper
airway, that are more prevalent in certain ethnic groups
might explain the comparable prevalence of OSA in
diverse populations.
Anatomical abnormalities of the
craniofacial region and upper airway. Several
craniofacial, orthodontic  skeletal or soft tissue
structural abnormalities such as  dysmorphisms related
to mandibular or maxillary size and position (e.g., a
posteriorly placed mandible, a narrow posterior airway
space), an enlarged tongue and soft palate, inferiorly
placed hyoid bone, and narrowed nasal cavities,  can
result in a  smaller or more collapsible upper airway,
and an increased predisposition for the development of
OSA.21 Adenotonsillar hypertrophy in childhood can
lead to abnormal growth patterns of the lower face and
jaw (adenoidal facies) and may predispose to OSA in
later life.18
Genetic predisposition. Apart from male sex the
strongest genetic correlate, a number of genetic linkages
have been found.22, 23 Familial aggregation of OSA has
been documented indicating a genetic basis for the
causation of OSA.24 Key contributory factors that
influence OSAS, such as obesity, craniofacial and
orthodontic abnormalities, ventilatory control, circadian
rhythm and sleep regulation, have a complex genetic
basis. However, it is difficult to disentangle
environmental risk factors, including cultural
differences in diet and lifestyle, from genetic factors.
Data are available linking circulating nuclear factor-κB
(NF-κB)-dependent genes, tumour necrosis factor-a
(TNF-α), and interleukin-8 (IL-8) to OSA23. Patients with
OSA have elevated circulating levels of TNF-α and it
has also been demonstrated that OSA is associated with
the TNF-α (-308A) gene polymorphism, which results in
increased TNF-α production.25
Modifiable Risk Factors
Excess body weight. Results of most studies
indicate that at least 60% to 70% of patients with obstru-
ctive sleep apnoea are obese.3-17 Potential mechanisms to
be considered include: (1) alteration in the upper airway
structure, (2) alteration in the upper airway function, (3)
alteration in the balance between ventilatory drive and
the load and (4) obesity induced hypoxemia.
There is little controversy regarding the causal role of
overweight in OSA but what is debated, is the
magnitude of association, the importance of specific
distribution of excess fat (general, central and  neck
obesity)  in the body and the variability of response of
OSA to excess weight. The present consensus is that
neck fat distribution26 and visceral fat26 correlate more
with OSA. A randomised study by Smith and co-
workers27 has shown that there occurs a 3% increase in
AHI for each 1% increase in body weight. Data are also
available from studies of surgical or dietary weight loss
interventions where a consistent and substantial
decrease in OSA severity following weight loss has been
demonstrated.28,29 While more than two-thirds of the
patients with OSA are obese, population studies
indicate that OSA is a considerable problem in non-
obese individuals also.13 Thus, when a non-obese
patient presents with a clinical picture suggestive of
OSA, the diagnostic possibility of OSA should not be
simply dismissed because the patient is not obese.
Alcohol consumption. Alcohol consumption
increases nasal and pharyngeal resistance and
compromises breathing during sleep. Most studies
including the MONICA II study30 have shown a
significant association of snoring and OSA with alcohol
consumption but what is not clear is the effect of long-
term alcohol use pattern, on the occurrence of the OSA.
Smoking. Smoking causes airway inflammation
and increases airway oedema, thus contributing to
OSA.31 In the only epidemiological study to focus on the
role of smoking in OSA, Wetter and co-workers found
that, current smokers were three times more likely to
have OSA than non-smokers.32
Nasal congestion. This is a potentially modifiable
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condition which predisposes to airway collapse and
hence OSA by increasing the pressure difference
between atmospheric and intrathoracic space to
maintain nasal breathing. It has been shown that the
odds ratio for habitual snoring and chronic severe nasal
congestion at night is 3.3.33
Menopause. Postmenopausal status has been
shown to increase the risk of OSA.20 The reasons are yet
unclear but hormone replacement therapy has
definitely improved OSA in postmenopausal women.34
Co-morbid Conditions
It is important to distinguish OSA from conditions, such
as hypothyroidism and acromegaly that can be
masquerading as OSA. Treatment of the primary
condition may provide a substantial cure for OSA.35 If
the primary condition is not identified, this may result
not only in a misdiagnosis but also a therapeutic
misadventure. The OSA is associated with diabetes
mellitus, hypertension, coronary artery disease,
myocardial infarction, congestive heart failure, stroke
and chronic renal failure. It is likely that the associations
may reflect risk factors that are common to all these
conditions and OSA. However, they may also reflect the
role of OSA in the aetiology of these conditions.
PATHOPHYSIOLOGY
Peculiarly, man’s best friend the dog (the bull dog)
remains his sole companion from among the mammals
to suffer from OSA. It appears the evolutionary
blessings of airway modification for speech and upright
posture have constitutionally predisposed humans for
OSA36 (Figure 1).
State-dependent reductions in respiratory muscle
activity are a normal phenomenon of sleep. Sleep apnea
patients differ from normal subjects in the sleep
dependent changes in respiratory drive to the upper
airway and pump muscles and anatomy and
biomechanical properties of the upper airway. The site
of sleep dependent obstruction in OSA is usually in the
retropalatal or the retroglossal regions or both.37-39 The
upper airway lumen is controlled by the net balance
between the constrictors and dilators of the pharynx,
which are in turn controlled by cranial motor nuclei (V,
VII, X, XI and XII).40 Sleep dependent changes in the
firing rates of these motor nuclei are mediated through
neurotransmitters, namely, serotonin, substance p,
thyrotropin releasing hormone, noradrenaline, orexin,
acetylcholine, glutamate are excitatory while glycine, γ-
amino butyric acid GABA and enkephalin are
suppressants.41 The predominant and non-rapidly
desensitising serotonin receptor subtype involved in
excitation of hypoglossal motor neurons (5HT
2a
) has
also been implicated in vasoconstriction (systemic and
pulmonary) and thromboembolism.42, 43 Its stimulation
has corrected sleep apnoea in animal models but side
effects make it an unlikely therapeutic target. Other
“orphan” receptors are under therapeutic evaluation.
Neuronal function per se is also altered in OSA, through
hypoxia and oxidative stress mediated damage of
hippocampal motor neurons and upper respiratory
neurons.44, 45 Magnetic resonance spectroscopy (MRS)
studies demonstrate altered neurometabolites (N-
acetylaspartate, phosphorylcreatine, myoinositol) in
hippocampus, and frontal lobe correlating with
Figure 1. Pathophysiology of obstructive sleep apnoea.
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increased cell damage.46 The role of various upper
airway reflexes in normal and OSA patients is also
under evaluation. These reflexes might contribute
significantly to upper airway activity in OSA patients
who otherwise have compromised central neural
drives.
Structural correlates of upper airway compromise in
OSA include retrognathia, maxillary repositioning,
intranasal obstruction, caudal displacement of hyoid
bone, macroglossia, low-lying or enlarged soft palate,
enlarged lymphoid tissue and brachycephalic posture.47
Skeletal predispositions are multi-factorial with
significant genetic influences that increase the likelihood
of OSA in some subjects.48 Soft tissue differences in the
form of oedema and fatty infiltration also confer
significant predispositions to OSA.49 Neck size is the
strongest of the obesity predictors for OSA and it
correlates with increased dimensions of parapharyngeal
fat pads.50 A larger upper airway soft tissue volume in
men may contribute to the increased prevalence of OSA
in men. During wakefulness also OSA subjects
demonstrate marked narrowing of the lateral airway
walls and this region is distended in OSA patients
treated with CPAP.
It is difficult to predict OSA severity reliably, solely
on the basis of imaging or muscle activity alone. The
biomechanics of the upper airway, altering compliance
and collapsibility determines snoring and apnoea. The
collapsible passage is formed by retropalatal and
retroglossal regions. Airflow through this passage is
influenced by variations in intra-luminal pressures,
resistance and collapsibility, according to Starling’s law.
The airway (nasal) pressure at which flow ceases in this
passage is termed as critical pressure (Pcrit). Normal
sleep decreases P
crit 
(-40cm H
2
O to -15cm H
2
O). Snorers
have a Pcrit  closer to -6cm, persons with hypopnoea near
-2cm and predominantly apneas occur when P
crit  
equals
atmospheric pressure.50 Nasal resistance contributes to
severity of OSA by limiting maximal flow upstream to
the collapsible passage and decreasing Pcrit. On the
contrary, positive airway pressure increases driving
pressure, airflow and hence Pcrit. The Pcrit is also affected
by length of the airway which is influenced by lung
volume which is normally decreased in sleep and more
so in OSA. Effect of supine positioning in aggravating
apnoea is independent of its effect on lung volumes.
Hysterical (shear stress dependent) properties of
mucosa and folds also influence collapsibility. Muscle
injury due to occasional high pressures and intermittent
hypoxia may contribute to disease progression. The
repeated systemic oxy-hemoglobin desaturations
caused due to apnoea place a substantial oxidative
burden on many physiologic systems contributing to
the systemic disease associations of OSA.51, 52
CONSEQUENCES OF OSA
Apart from direct consequences of repetitive airway
obstruction, the vicious cycle of hypoxia, sympathetic
stimulation and arousal produces a significant oxidative
load on all physiologic systems of the body. The damage
is reflected initially in impaired endothelial function,53
manifested through increased  expressions of cell
activators NF-κB,52 adhesion molecules vascular
endothelial growth factor (VEGF),54 inflammatory
mediators like cytokines and other markers high
sensitivity-C reactive protein (hs-CRP), intercellular
adhesion molecule-1 (ICAM-1), interleukins 6 and 18,56
activated monocytes,51  markers of apoptosis  and
remodeling. Patients with predisposing genetic
polymorphisms are more prone to the deleterious
effects of OSA, demonstrating accelerated progression
of atherosclerosis.25
Hypertension
Population-based studies show that the prevalence of
hypertension is greater in patients with OSA.57 Studies
in hypertensive subjects show a higher incidence of
OSA.58, 59 Data from the Wisconsin Sleep Cohort Study,58
showed a dose response association between SDB at
baseline and development of new onset hypertension
four years later independent of other known risk factors
[odds ratio (OR) for AHI <5, 5-15, >15 were 1.42, 2.03
and 2.89 respectively].58  Further, in some studies CPAP
therapy has been reported to reduce elevated blood
pressure in hypertensive OSA subjects.60 In OSA acute
nocturnal surges in blood pressure occur due to
chemoreflex mediated hypoxia induced sympathetic
stimulation. These are potentiated in hypertensive
subjects, increasing peripheral resistance. When the
apnoea ends, changes in intrathoracic pressure increase
the cardiac output, on a constricted vascular bed
causing surges in blood pressure. “Carry over” of the
elevated sympathetic tone leads to increased daytime
blood pressures. Normotensive OSA patients without
overt cardiovascular risk factors, have been shown to
have decreased heart rate variability and increased
blood pressure variability, which predispose to
hypertension and endorgan damage. Chemoreceptor
“resetting”, tonic chemoreceptor activation occur even
in normotensive patients with OSA. Endothelial
dysfunction and remodeling may lead to increase wall
lumen ratio and contribute to progression of
hypertension (Table 4).
Heart Failure
Patients with systolic heart failure have a high
prevalence of sleep apnoea predominantly central sleep
apnoea (CSA).61 Patients with diastolic dysfunction may
have a higher prevalence of OSA.61 Studies suggest that
during the night the proportion of CSA goes on
increasing, from the first to the last quarter.61 Heart
failure predisposes to OSA by increased soft tissue
oedema, increased airway collapsibility and prolonged
circulation times. Cardiac function is deranged in OSA
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due to hypoxia, increased peripheral resistance (due to
respiratory efforts), oxidative stress, increased
atherosclerosis, and risk of arrhytmias. Treatment with
CPAP therapy has been shown to increase stroke
volume and improve functional status in patients with
heart failure.62 Thus, OSA in the backdrop of heart
failure requires aggressive treatment.63
Cerebrovascular Disease
Breathing disorders consequent on a cerebrovascular
attack, are more likely to cause primarily central sleep
apnoea.64 They are most likely to manifest in the initial
hours after stroke,65,66 but may aggravate pre-existing
OSA.  Prevalence of OSA is equally high in subjects with
transient ischemic attacks,66-68 suggesting against a
causal association. The severity of obstructive events is
independent of the type of stroke and localisation in the
brain.67 It is hypothesised that intermittent hypoxia
along with its consequent sympathetic stimulation,
hypertension and oxidative stress leads to disturbed
autoregulation of cerebral blood flow, platelet activation
and endothelial dysfunction which may precipitate a
stroke in patients with OSA. The use of CPAP in the
treatment of post-stroke OSA has been effective69 in
improving quality of life and abolishing apnoeas.
Pulmonary Artery Hypertension
Several studies show no difference between pulmonary
hypertensive and normotensive subjects with OSA with
respect to nocturnal oxygen saturation and AHI.70, 71
This suggests that individual variation in pulmonary
vascular sensitivity or factors other than OSA per se,
may be responsible for pulmonary artery hypertension.
Intriguingly, CPAP therapy has been shown to decrease
pulmonary artery pressure in patients with OSA with
either increased or with normal pulmonary artery
pressures,72, 73 which suggests that even “normal” may
be elevated when compared with baseline.74
Arrhythmias
The most commonly associated arrhythmia with OSA is
sinus bradycardia with AV blocks (sinus arrest and
complete heart block).75 It is caused by increased vagal
tone linked with apnoea severity. However in subjects
with underlying cardiac disease, it can even precipitate
tachyarrhythmias.75 Recurrent sympathetic stimulation
at the termination of an apnoea adds to the risk of fatal
arrhythmias. Untreated OSA is an important under
recognised cause of sudden cardiac death.76 Treatment
with CPAP therapy has been shown to abolish these
triggered arrhythmias and is the first line treatment in
patients with a compromised heart.
Insulin Resistance and Metabolic Syndrome
Animal studies have demonstrated the significant
“stress” of intermittent hypoxia in disturbing the
glucose-insulin axis.77 Sleep fragmentation has also been
demonstrated to disturb glucose tolerance in adults.78
Sleep apnoea patients also have in addition, “visceral
obesity” which contributes to their predisposition for
insulin resistance.  There have been conflicting reports
from studies trying to assess the independent
contribution of sleep apnoea to insulin resistance.
Though similar methods of measurement, homeostatic
model assessment for insulin resistance (HOMA-IR)79-83
have been used in the studies, the confounding effects
of obesity on insulin resistance can’t be eliminated.80, 84
Insulin resistance is a known risk factor for
atherosclerosis. The OSA represents a stress that
promotes insulin resistance and hence development of
metabolic syndrome and finally atherogenesis as
reflected in a number of studies which suggest
association with OSA severity. Each additional apnoea
or hypopnoea increases the fasting insulin level and
HOMA-IR by about 0.5 percent.82 Metabolic syndrome,
the clustering of metabolic and morphological risk
factors including insulin resistance is a well established
risk factor for cardiovascular disease.85, 86 Interaction of
OSA with various vascular risk factors (called
Syndrome Z) has long been recognised.87 Though
previous studies have shown an independent
association between OSA and individual components of
metabolic syndrome, the overall association of
metabolic syndrome independent of obesity has been
shown only recently.84 However, the issue remains
controversial and obesity may be a more significant
factor in impairing metabolism.80, 84 Comparative
assessments of metabolic abnormalities and hs-CRP
levels in carefully matched obese controls, non- obese
controls and OSA patients have failed to reveal
significant differences.81, 88 Results from small cohort
studies suggest that CPAP therapy which abolishes
apnoeas and hypopnoeas also improves insulin
resistance.83
Neurocognitive Sequelae of Obstructive Sleep
Apnoea
Excessive sleepiness and impaired functioning can
Overview and Implications of Obstructive Sleep Apnea H. Sharma and S.K. Sharma
Table 4. Consequences of untreated obstructive sleep apnea
Odds Ratio Reference
Cardiovascular
Prevalent HTN 1.4 Nieto et al57
Incident HTN 2.9 Peppard et al58
CAD 1.3 Shahar et al59
Stroke 4.5 Pozza et al64
CCF 2.4 Shahar et al59
Sudden death # Gami et al76
Neurocognitive
Vehicle accidents 7 Teran-Sentos et al89
Metabolic effects
Insulin resistance # IP et al82
#=Odds ratios were not provided, HTN=Hypertension,
CAD=Coronary artery disease, CCF=Congestive cardiac failure
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seriously disturb the lives of patients with OSA. These
patients have a seven times higher risk of automobile
accidents.89 Moreover, self-awareness about this possible
hazard even among diagnosed patients is low.90
Cognitive areas most frequently and reliably reported as
being affected by OSA are general intelligence,
attention, memory and executive and motor
functioning.91 Patients with OSAS suffer from excessive
daytime sleepiness (EDS) due to: fragmented sleep and
nocturnal hypoxemia. Recent work indicates that these
two factors are differentially related to the
neurocognitive deficits observed in OSAS. The EDS
specifically relates to reduced attention and memory
while hypoxemia specifically relates to reduced
executive functioning reflected in impaired decision
making.
CLINICAL PRESENTATION
Snoring and excessive daytime somnolence are the
cardinal features of sleep apnoea syndrome. Prevalence
of OSA has been reported to be 35% to 64% in habitual
snorers.13,16 The various symptoms of OSA patients are
summarised in table 5. Hypoxemia, hypercapnia, and
cor-pulmonale may complicate the late stages of the
obstructive sleep apnoea syndrome, especially when
obesity and chronic lung disease are present. Death can
result from severe episodes of apnoea. Reference has
already been made above to conditions, like hypo-
thyroidism, acromegaly which may masquerade as
OSA.92
disorder characterised by unpleasant sensations in the
legs and an uncontrollable urge to move when at rest in
an effort to relieve these feelings. The most distinctive or
unusual aspect of the condition is that lying down and
trying to relax activates the symptoms. More than 80%
of the people with RLS also experience a more common
condition known as periodic limb movement disorder.
It is characterised by involuntary leg twitching or
jerking movements during sleep that typically occur
every 10 to 60 seconds, sometimes throughout the night.
The symptoms cause repeated awakening and severely
disrupted sleep. Patients are often unable to
concentrate, have impaired memory, or fail to
accomplish daily tasks. The diagnosis is based heavily
on history and symptoms, hence should be kept in
mind. Overnight polysomnography study may suggest
a diagnosis of periodic limb movement disorder.
Assessment of Sleepiness
Subjective assessment. This involves the use of
focused sleep questionnaires, validated in various
studies and demonstrated to have a reasonably high
sensitivity 74 percent to 86 percent.93 In the Epworth
Sleepiness Scale (ESS), the patient rates his or her
propensity to fall asleep during eight situations ranging
from lying down to rest, to sitting, to conversing. The
likelihood of falling asleep is rated on a scale from 0 to
3, with 3 representing the highest likelihood of falling
asleep. The total score ranges from 0 to 24, with a score
of less than 7 considered within normal limits and a
score of greater than 9 suggestive of sleep-disordered
breathing. The Stanford Sleepiness Scale (SSS) rates
subjective sleepiness on a scale from 1 to 7 with alert
and wide awake as 1, a little foggy as 4 and almost
asleep as 7. It is worthwhile to remember that sleep
deprivation due to any cause can elevate the ESS or SSS
scores.
Objective assessment
Multiple sleep latency test (MSLT). The MSLT is
an objective test in which a patient is given four or five
20-minute opportunities to fall asleep at set intervals
during the day (usually every two hours).93 The
tendency of a patient to fall asleep in a comfortable
setting is measured. It is considered a reliable, validated
measure of sleepiness, but does not correlate strongly
with severity of OSA. The mean latency to sleep onset is
helpful in differentiating patients with normal alertness,
who have a mean sleep latency of more than five
minutes, from those with excessive daytime sleepiness,
whose mean latency is less than five minutes. The types
of sleep that occur are also diagnostically useful. It is
quite common in narcolepsy to observe two or more
sleep-onset REM (SOREMs) periods in the five naps in
a patient who otherwise had a normal night of sleep
preceding the test. The MSLT is purported to be helpful
Table 5. Clinical presentations in patients with obstructive sleep
apnoea
Daytime Symptoms Sleep Symptoms
Excess daytime sleepiness Snoring
Cognitive and memory impairment Choking
Executive dysfunction Nocturnal polyuria
Erectile dysfunction Restless sleep
Gastroesophageal reflux Dryness of mouth
Morning headache
DIAGNOSIS
An outline of the diagnostic approach to OSA is
provided in figure 2. A high index of clinical suspicion
is essential in detecting OSA, since patients’ awareness
regarding the problem is low (especially in mild and
moderate cases). Often the patient seeks help for
associated problems like hypertension, headaches, dry
mouth, fatigue, erectile dysfunction etc. The differential
diagnosis of OSA includes other sleep disorders, like
narcolepsy, restless legs syndrome, nocturnal seizures
and idiopathic hypersomnia. Narcolepsy characterised
by “sleep attacks”, cataplexy, and excessive daytime
sleepiness can be readily differentiated by sleep latency
testing. Restless legs syndrome (RLS) is a neurological
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in making a diagnosis of several other types of sleep
disorders as well as in assessing the results of the
treatment.
The MSLT has limitations, for example, it does not
control for the mental state of the person tested and
assumes the ability to fall asleep is directly associated
with sleepiness, which may not always be the case. This
test is optimally performed just after an overnight PSG,
because disturbances in the quality or quantity of sleep
the night before will influence the results obtained on
the MSLT and may lead to a false-positive result.
Maintenance of wake test. It is similar in concept to the
MSLT with the tendency to sleep being assessed on
exposure to multiple stimuli.93
Polysomnography
Overnight PSG is required to make a diagnosis of OSA.
The PSG consists of a modified electroencephalogram
(EEG) to monitor brain activity, bilateral electro-
oculogram (EOG) to monitor eye movement, submental
and anterior tibialis electromyogram (EMG) to monitor
limb activity, oral and nasal thermistors to monitor
airflow, chest-wall and abdominal piezoelectric bands
and intercostal EMG to monitor respiratory effort, ear or
finger pulse oximetry to monitor arterial oxygen
saturation (SaO2), and V1 telemetry to monitor cardiac
activity. Electrocardiography (ECG) may also be
included. Respiratory effort may be monitored by
respiratory inductance plethysmography or esophageal
manometry.  Overnight PSG study provides data on the
RDI, AHI, AI, and the lowest oxygen saturation (LSAT).
Continuous esophageal and pharyngeal pressure
measurements may be added to indicate respiratory
effort and to help determine the site of obstruction.
Night-to-night variability in PSG findings due to inter-
observer differences in scoring, variability in sleeping
position, alcohol ingestion, or nasal congestion may
explain seemingly inconsistent results within individual
patients and the lack of correlation between
symptomatic improvement and sleep test results.93
In patients with OSA who are advised CPAP
treatment, there is a need for a repeat PSG study for
titration of appriopriate CPAP pressure for abolition of
apnoeas and hypopnoeas. Often this separate PSG
study is clubbed with the diagnostic PSG as a “split-
night” study. The advent of auto-adjusting pressure
titrating CPAP (A-CPAP) has enabled us to avoid the
repeat overnight PSG and directly use the A-CPAP.94
They have been used successfully for initial diagnosis
also.94
Alternatives to overnight PSG. If, the estimated
prevalence of sleep apnoea at 2 to 4 percent of middle-
aged adults is accurate, then the material and
manpower costs of full PSGs to diagnose all suspected
cases would be prohibitive. Diagnostic approaches
• Sleep history
• Anthropometry: BMI, PPNC,
waist/hip ratio
Assessment of sleepiness:
• Subjective: ESS, SSS
• Objective: MSLT*, MWT*
Alternatives:
• Partial channel PSGs
• Home monitoring devices:Actigraphy
• Radiology: CT, MRI, Cephalometry
• Functional Imaging: Endoscopy, Acoustic reflecions
• Automatic pressure titrating CPAP
CLINICAL SUSPICION
Figure 2. Algorithm for diagnosis of obstructive sleep apnea.
*=Ideally MSLT, MWT should be performed after a full night sleep, mostly after the PSG; BMI = Body mass index; PPNC = Percent
predicted neck circumference; ESS = Epworth sleepiness scale; SSS = Stanford sleepiness scale; MSLT = Multiple sleep latency test;
MWT = Maintanence of wake test; PSG = Polysomnography; CT = Contrast tomography; MRI = Magnetic resonance imaging;
CPAP = Continuous positive airway pressure.
PSG
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which might be viewed either as alternatives to PSGs or
as screening tests to better select patients for PSG
include:93
1. Partial channel PSGs;
2. Partial night or daytime PSGs;
3. Portable sleep monitoring devices for use at home:
actigraphy;95
4. Automatic pressure titrating CPAP based direct
pressure titration study in suspected sleep apnoea
patients for diagnosis and management;95
5. Radiology: imaging of the head and neck for
anatomic abnormalities predictive of sleep apnoea:
cephalometry, magnetic resonance imaging (MRI),
acoustic reflections and computed tomography
(CT) scans; and
6. Anthropomorphic measurements: such as neck
circumference nasopharyngeal and laryngeal
endoscopic measurements of both structure and
function.
Prediction equations. Combinations of patient
symptomalogy, anthropometry and demographic
patterns have been modeled variously to arrive at
prediction equations.96-98 One such model developed
and validated in subjects in New Delhi had a sensitivity,
specificity, positive predictive value and negative
predictive value of 91.3%, 68.5%, 70.5% and 92.3%,
respectively.98 The application of these models may help
more efficient use of the already scarce sleep medicine
facilities. Future incorporation of multiple airway
parameters with mathematical modeling may increase
accuracy.
TREATMENT
Lifestyle Modification
Weight reduction is undisputedly helpful in improving
the severity of OSA. As referred previously there occurs
a 3% increase in AHI for each 1% increase in body
weight.27 Weight reduction by as little as 3-5 kg has been
shown to significantly decrease snoring, CPAP
pressures and AHI.28 However, this does not abolish
OSA. Weight reduction is expected to ameliorate some
of the risk for co-morbid conditions like CAD,
hypertension, metabolic syndrome. Both sedative
medications and alcohol have a depressant effect on the
pharyngeal dilator muscles and increase respiratory
resistance, aggravating OSA. In subjects with evidence
of chronic or nocturnal nasal congestion, treatment with
topical steroids, antihistamines and surgery may help in
reducing severity of OSA. Decrease in nasal congestion
also helps to improve CPAP compliance (Figure 3).
Pharmacological Treatment
A number of agents have been tried without success to
PSG (Rule out hypothyroidism)
and other reversible causes of OSA
AHI 5-15/hr
(Mild) AHI 15-30/hr
(Moderate)
AHI >30/hr
(Severe)
Asymptomatic: Lifestyle modification
Symptomatic:
• Lifestyle modification
• Modafinil for EDS*
• Use of CPAP
Symptomatic:
•  Lifestyle modification
•  Rhinolaryngologist review
•  Use of CPAP
•  Modafinil for EDS*
CPAP intolerant:
• OA
• Consider BIPAP ±
• Surgery
Asymptomatic: Lifestyle modification
CHF†, CAD†, arrhythmias†:
CPAP therapy
• Lifestyle modification
• Rhinolaryngologist
review
• Use of CPAP
• Modafinil for EDS*
CHF†, CAD†,
arrhythmias†:
 CPAP therapy
Figure 3. Algorithm for the management of obstructive sleep apnea.
PSG = Polysomnography; AHI = Apnea-hypoapnea index; CPAP = Continuous positive airway pressure; EDS = Excessive daytime
sleepiness; CHF = Congestive heart failure; CAD = Coronary artery disease; OA = Oral appliances; * = Avoid in subjects with CHF,
CAD and exercise caution in patients with LVH; † = Maximal benefit with CPAP; ± = high CPAP pressures,underlying lung disease;
CHF = Congestive heart failure, CAD = Coronary artery disease.
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ameliorate the excessive somnolence in OSA patients.
The US FDA has approved the use of the wake
promoting drug modafinil in improving alertness and
subjective and objective sleepiness in patients with
OSA.99 The exact mode of action is unknown. It
decreases the uptake of norepinephrine and dopamine,
stimulates glutaminergic pathways and blocks
“hypocretin” mediated pathways in the hypothalamus.
It is contraindicated in patients with significant cardiac
dysfunction. It has also shown a weight reducing effect
across various studies, which may further benefit OSA
patients.100, 101 The starting dose is 200mg in the morning
after waking and can be titrated upwards. Headache
(11%) and nausea (12%) have been the commonest
reported adverse effects.99 More selective (R-
enantiomer) molecules are also available.
Positive Pressure
Therapy with CPAP is the first-line treatment for OSA.102
It delivers air at high flow (20-30 litres/min) through an
interface to the upper airway, providing a constant
mechanical splint (air at pressure) to prevent airway
collapse during sleep, thus abrogating apnoeas and
hypopnoeas.103 This reduces intermittent hypoxia,104, 105
respiratory effort, sympathetic stimulation,105 arousals105
and sleep fragmentation. Recent meta-analyses indicate
that the treatment of OSA with CPAP therapy leads to
significant improvement in daytime sleepiness and
quality of life measures as well as reduced diastolic and
systolic blood pressure.102, 106 Currently, CPAP is
recommended for any patient with symptoms, though
maximum benefit has been observed in patients with
AHI greater than 20 per hour.107 It is the treatment of
choice for severe OSA and in subjects with
cardiovascular dysfunction.106 Results  of a recent study
with CPAP therapy  show  a significant improvement in
markers  of early atherosclerosis in  patients  of  mild to
moderate  OSA  with no symptoms.108 Though the
overall magnitude of risk reduction is unknown, the
indications for CPAP therapy may widen in the future.
Retrospective cohort studies comparing compliance
with CPAP use in patients with severe OSA suggest a
reduction in mortality (85.5% vs 96.4%).109, 110 Bullous
lung disease and recurrent nasal/ear infections are
relative contraindications. The theoretical risks of
positive pressure; pneumoencephalus, increased
intraocular pressure are rare. Despite its efficacy patient
compliance is unsatisfactory ranging from 36% to 60%
across studies.102 Compliance failure due to discomfort
can occur due to many reasons, like ill fitting face
masks, claustruphobia and eustachian tube
dysfunction.102, 106 Interface designs for CPAP have been
developed over the years in an effort to minimise the
occurrence of such adverse effects and to improve
compliance. The results of a meta-analysis suggest that
nasal pillows or the Oracle oral mask may be useful
alternatives when a patient is unable to tolerate
conventional nasal masks.111 The face mask can not be
recommended as a first-line interface, but may be
considered if nasal obstruction or dryness and
uncontrolled air leakage from mouth limits the use of a
nasal mask.111 Appropriate pressure titration, proper
masks, nasal decongestants and counselling should
help. Humidified air at appropriate temperature
(warmed or cooled) may help with nasal dryness.
Newer respiration timed pressure delivery modes like
A-CPAP and pressure relief CPAP are more
comfortable. In contrast to the conventional fixed
pressure (F-CPAP) in which the pressures remain
constant throughout sleep, in A-CPAP the pressure
delivered to the airway fluctuates with sleep. Apart
from better patient comfort, the A-CPAP is significantly
more effective in correcting the deranged metabolic
parameters in OSA patients.112 However, the A-CPAP is
up to three times costlier than the conventional F-CPAP
and patients should be given a trial of cheaper options,
appropriate interface devices and counselling before
prescribing an A-CPAP.   The A-CPAP has been tried for
primary diagnosis and management of suspected OSA
patients, with acceptable results and may be beneficial
in resource limited settings.94, 113 Patients intolerant to
CPAP may try uvulopalatopharyngoplasty or oral
appliances.
Bilevel airway pressure therapy (BiPAP). The
CPAP provides similar inspiratory and expiratory
pressures, however, in BiPAP the inspiratory positive
pressure (IPAP) is set to prevent upper airway closure
and hypopnoea due to partial closure. The expiratory
Overview and Implications of Obstructive Sleep Apnea H. Sharma and S.K. Sharma
Table 6. Surgical procedures for obstructive sleep apnoea
Surgery Indication Result
Septoplasty Deformed septum Improved CPAP tolerance
Nasal polypectomy Airway obstruction Improved CPAP tolerance
Adenoidectomy Enlarged tonsils Treats OSA (esp. children)
Uvulopalatopharyngoplasty Debulking soft palate Treats snoring, decreases AHI, long-term success rate 52.3%
Pillar procedure Stabilises soft palate Decreases snoring and  AHI
Hyoid suspension Enlarges hypopharyngeal airway Helps moderate OSA, can cause dysphagia
MMA Stepwise jaw reposition In selected patients efficacy equals CPAP
CPAP = continous positive airway pressure; OSA = obstructive sleep apnoea; AHI = apnoea-hypopnoea index;
MMA=Mandibular advancement genioglossus recession maxillary advancement
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positive airway pressure (EPAP) serves to stabilise the
collapsible airway at end expiration such that the
patient can comfortably trigger the delivery of an IPAP.
It provides ventilatory assistance with improved patient
compliance. It can be particularly helpful in patients
with high CPAP pressures and underlying lung diseases
compromising oxygen transfer or increasing the work of
breathing.107
Oral Appliances
The US FDA approves 16 devices for use in sleep
apnoea. Oral appliances (OA) are now widely used as
an alternative to CPAP therapy. They are designed to
keep the upper airway open by either advancing the
lower jaw forward or by keeping the mouth open
during sleep. A recent meta-analysis found that OA
should not be considered as the first choice therapy for
OSA,114 where symptoms and sleep disruption are
severe.  Although CPAP was clearly more effective at
reducing the disruption to sleep, some people with
OSAH may prefer using OA if they are found to be
tolerable and more convenient than CPAP. When an
active OA was compared with an inactive OA, there
were improvements in daytime sleepiness and apnoea/
hypopnoea severity. Also, OA may be more effective
than corrective upper airway surgery.
Surgery
Continuous positive airway pressure provides at best a
control for OSA. It is surgery alone which can provide a
“cure”. However, the role of surgery requires proper
patient assessment and selection and is not for
everyone.114 Uvulopalatopharyngoplasty (UPPP) is the
most common surgery performed for snoring. It has
been shown to decrease OSA severity, more so in
patients with retropalatal obstruction. This surgical
procedure has an approximately 52.3% rate of long-term
reduction of respiratory disturbance index (RDI) or AHI
of  greater than 50% of patients with mild or moderate
sleep apnoea.114, 115 Site-specific surgery, including
maxillomandibular advancement, has been shown to be
effective in selected patients with certain anatomical
abnormalities. Tracheostomy is reserved for patients
with severe OSA and cardiorespiratory compromise in
whom positive airway pressure is neither tolerated nor
effective. Table 6 provides a list of surgical procedures
available for the treatment of symptomatic anatomical
obstructions of the upper airway that contribute to or
result in clinical OSA.115
Radiofrequency ablation of the soft palate and
tongue base employs the administration of microwave
radiofrequencies to the treated tissue of the soft palate
and/or the tongue base with a needle-implanted probe.
This modality has been predominantly used for the
treatment of snoring by treating the soft palate.
Mandibular advancement, genioglossus recession and
maxillary advancement (MMA) is successful for
patients with base of tongue obstruction, severe OSAS,
morbid obesity, and failure of other treatments.116 With
careful evaluation, results with MMA surgery equal
those of nasal CPAP.117 The Stanford Group116 has
outlined a specific surgical protocol that is phased and
tailored to the specific anatomical abnormalities in each
patient.
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